Perivascular inflammation is a prominent pathologic feature in most animal models of
pulmonary hypertension (PH) as well as in pulmonary arterial hypertension (PAH) patients …

Therapeutic options for pulmonary arterial hypertension (PAH) have increased over the last
decades. The advent of pharmacological therapies targeting the prostacyclin, endothelin …

Inflammasomes are components of the innate immune response that have recently emerged
as crucial controllers of tissue homeostasis. In particular, the nucleotide-binding domain …

Pulmonary arterial hypertension (PAH) is a severe but treatable form of pre-capillary
pulmonary hypertension caused by pulmonary vascular remodelling. As a result of basic …

Cardiovascular disease is the leading cause of morbidity and mortality world-wide. Recently,
the role of inflammation in the progression of diseases has significantly attracted …

The NLRP3 inflammasome has been implicated in the development and progression of
heart failure. The aim of this study was to determine the safety of an oral inhibitor of the …

Pulmonary hypertension is a progressive and often fatal cardiopulmonary condition
characterised by increased pulmonary arterial pressure, structural changes in the pulmonary …

Right ventricle (RV) dysfunction is the strongest predictor of mortality in pulmonary arterial
hypertension (PAH), but, at present, there are no therapies directly targeting the failing RV …

Background: Macrophages are involved in the pathogenesis of pulmonary arterial
hypertension (PAH). Caspase-8, an apical component of cell death pathways, is significantly …

Background: Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension
(PH) characterized by obliterative pulmonary vascular remodeling, resulting in right-sided …